Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02939950 · ClinicalTrials.gov registry record · NA
Silicone Hydrogel Soft Contact Lens 7-Day Extended Wear Basis
A NA study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- NA
- Development phase
- 816
- Enrollment target
NCT02939950: Completed NA study, sponsored by Bausch Health Americas.
NCT02939950 is a NA study that has completed, run by Bausch Health Americas. The registered enrollment target is 816 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02939950, a NA study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- NA
- Development phase
- 816 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and effectiveness of the Bausch + Lomb samfilcon A soft (hydrophilic) contact lens, a new silicone hydrogel contact lens, compared to the Bausch + Lomb PureVision® soft contact lens when worn for 7-day extended wear by adapted soft contact lens wearers.
Primary Outcome
For determination of high contrast visual acuity (VA), the participant was seated at the photoropter so that the distance from the participant's eyes to the logMAR chart was 6.5 feet (2.0 meters). The chart was at eye level for each participant. The logMAR charts had two alternative letter sequences from 28 letters (0.3 logMAR) to 62 letters (-0.3 logMAR). The visual acuity was measured through the phoropter using the distance refractive correction with the addition of +0.50 Diopter to compensat
Interventions
- DEVICE Bausch + Lomb Samfilcon A Soft Contact Lens
- DEVICE Bausch + Lomb Pure Vision Soft Contact Lens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 816 participants |
| Start Date | 2015-04-30 |
| Est. Completion | 2016-08-03 |
| Phase | NA |
What the finished NCT02939950 record still lists
NCT02939950 is an interventional study that assigns participants to a tested intervention. The registered 816 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 2 interventions - of which Bausch + Lomb Samfilcon A Soft Contact Lens is the first listed.
NCT02939950 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02939950 about?
NCT02939950 is a clinical study titled "Silicone Hydrogel Soft Contact Lens 7-Day Extended Wear Basis". The objective of this study is to evaluate the safety and effectiveness of the Bausch + Lomb samfilcon A soft (hydrophilic) contact lens, a new silicone hydrogel contact lens, compared to the Bausch + Lomb PureVision® soft contact lens when worn for 7-day extended wear by adapted soft contact lens w...
What is the current status of trial NCT02939950?
This trial is currently completed. It is a NA study. The enrollment target is 816 participants. The study started on 2015-04-30. Estimated completion is 2016-08-03.
What interventions are being tested in trial NCT02939950?
The interventions under investigation include: Bausch + Lomb Samfilcon A Soft Contact Lens (DEVICE), Bausch + Lomb Pure Vision Soft Contact Lens (DEVICE).
Who is sponsoring clinical trial NCT02939950?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02939950's enrollment target sits among peer trials
816 134th of 2000 higher than 1,867 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07218029 · 815 participants · Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
- NCT04846959 · 818 participants
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
- NCT04613440 · 820 participants · NA
FaCT Trial (Facilitated Cascade Testing Trial)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI